Articles tagged with Chemotherapy
A groundbreaking study uses machine learning to predict treatment resistance in cervical cancer by analyzing genetic mutations. The algorithm identified molecular assemblies driving treatment resistance and pinpointed tumors most susceptible to therapy, resulting in improved patient outcomes.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
A new trial found that combining anti-angiogenic drugs with chemotherapy led to more young people seeing their tumors shrink, from 18% in the control group to 26%. Patients who received Bevacizumab additionally had better one year progression-free survival rates.
Researchers have identified a gene that links deafness to cell death in the inner ear, creating new opportunities for preventing hearing loss. The discovery suggests that UPR-blocking drugs could prevent deafness caused by loud noise exposure or aging.
Researchers created nanoparticles using ultraviolet light crosslinked amino acids, loaded with doxorubicin and coated with tannic acid complex. The nanoparticles exhibited superior stability and drug release under different pH conditions, showing excellent anticancer activity in tumor-bearing mice.
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
Researchers have developed a novel method to produce a selective anticancer precursor substance. The synthesis involves the reaction of metal-active oxygen species with nitrile, utilizing cost-effective metals at lower temperatures. This breakthrough opens up new possibilities in developing innovative drugs against cancer.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
The combination of atezolizumab and carboplatin improved overall survival by 3.9 months, and lengthened progression-free survival from 2.2 to 4.1 months. Patients with higher body mass indexes and uncontrolled blood glucose levels showed greater benefits.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
A phase III clinical trial found that neoadjuvant chemotherapy can downstage lymph node-positive breast cancer, allowing patients to safely omit adjuvant regional nodal irradiation. This treatment de-escalation strategy is an option for patients whose lymph nodes become cancer-free after neoadjuvant treatment.
Researchers from Japan have discovered a novel targeted molecular therapy using microRNA-451a to suppress the progression of gemcitabine-resistant biliary tract cancers. The study found that miR-451a significantly diminished cell proliferation, induced cell death, and reduced chemoresistance in cancer cells.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A new AI tool combines cancerous and non-cancerous cell patterns to predict breast cancer outcomes, allowing for more precise treatment plans. This could lead to reduced chemotherapy duration and intensity for some patients.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Researchers from ICMR-National Institute of Nutrition advocate for repurposing non-cancerous drugs to target Cancer Stem Cells (CSCs), which are resilient to conventional treatments. The study identified a range of non-cancer drugs with potential to target CSCs directly, and combining these with micronutrients amplifies their anticance...
A study of 103,000 early-stage breast cancer patients reveals a significant racial disparity in chemosensitivity and survival rates. Black patients are more likely to experience residual disease after neoadjuvant chemotherapy, leading to a higher mortality risk.
Researchers investigate nanoparticles for cancer treatment, hoping to reduce side effects and improve efficacy. La-Beck's lab aims to understand the body's interaction with nanoparticles and their impact on tumor growth and immune responses.
Two phase-3 clinical trials demonstrate a significant increase in overall survival and progression-free survival for bladder cancer patients treated with immunotherapy combinations. The studies show a 22% reduction in the risk of death compared to chemotherapy alone, providing a promising new approach for treating advanced bladder cancer.
Researchers developed nanoparticles to transport Gemcitabine directly into tumors, increasing efficacy and sparing healthy cells. The approach shows potential to treat pancreatic carcinomas more accurately and with reduced side effects.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
Patients with breast cancer in conflict zones face significant barriers to treatment, including lack of standard procedures and funding for rebuilding capacity. This results in many patients being diagnosed with advanced breast cancer, often with limited palliative care options.
Researchers discovered narrow-spectrum Wnt signaling inhibitors can suppress breast cancer tumors and reduce chemo-resistant cells in mice. The treatment, derived from a bacterial toxin, targets specific receptors to minimize bone density side effects.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
New research suggests that vitamin D supplements can reduce the risk of peripheral neuropathy in patients undergoing paclitaxel treatment. The study found that patients with vitamin D deficiency were more likely to experience severe neuropathy, and that inducing vitamin D deficiency caused similar symptoms in a mice model study.
A specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way. Increasing GTP levels makes cells resistant to treatment, while lowering them makes cells more sensitive.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
New study reveals that microtubule poisons effectively treat cancer by causing abnormal cell division, leading to tumor cell death. The findings contradict decades-long assumptions about the mechanism of action of these drugs.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A new study from Columbia University Irving Medical Center suggests that chemotherapy-induced cognitive impairment, or 'chemobrain', may be caused by an excess of calcium floating around inside cells. The research could lead to new treatments to restore cognition in patients experiencing symptoms.
Researchers developed a nanotechnology method to deliver medication through the blood-brain barrier, overcoming its selectivity and expanding therapeutic options for glioblastoma treatment. The technique demonstrated improved tumor shrinkage and survival rates in mice, paving the way for further preclinical studies.
A new study published in JNCCN found that intensive local-regional treatment to remove as much tumor as possible did not significantly impact overall quality of life for patients with metastatic colorectal cancer. However, the treatment was associated with a higher risk of adverse events.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
A VHIO-led study has identified DPPA3 as a regulator of dormant cancer cells and chemoresistance in colorectal cancer. High levels of DPPA3 are found to predict disease relapse, while HIF1 is proposed as a potential therapeutic target to sensitize CRC cells to chemotherapy.
Research reveals increased sympathetic nerve activity and reduced exercise capacity in patients with heart failure resulting from anthracycline chemotherapy. Sympathetic neural overdrive is associated with skeletal myopathy and decreased cardiac function.
Researchers have developed a new approach to treating invasive bladder cancer, combining chemotherapy and immunotherapy, which may preserve quality of life. In a phase 2 clinical trial, approximately 43% of patients achieved complete response without surgical removal of the bladder.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers developed a novel material that self-assembles into micelle structures targeting cancer cell lysosomes, specifically interacting with Cathepsin B. This leads to dysfunctional lysosomes and apoptotic death of cancer cells. The technology promises a new approach to combat drug resistance in cancer treatment.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
A Brown University team developed a hydrogel-based delivery system that balances tumor acidity and increases doxorubicin's effectiveness against cancer cells. Initial lab tests show promising results, paving the way for pre-clinical trials.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
A large-scale international study of childhood cancer survivors found that women who received high-dose doxorubicin chemotherapy without chest radiation have a significantly increased risk of breast cancer before age 40. The researchers are calling for broadening guidelines for breast cancer screening in these patients.
Researchers at Hollings Cancer Center have made a breakthrough in CAR-T-cell therapy by eliminating the need for lymphodepleting chemotherapy, which reduces the risk of severe side effects. In preclinical models, their method showed promising results in controlling cancer and creating memory cells trained on specific proteins.
A subgroup analysis found that patients with an NPM1 mutation had a 48% reduced risk of death compared to those without the mutation. Patients receiving supplementation experienced lower rates of bacterial infections, bleeding, and inflammation during intensive chemotherapy.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Breast cancer survivors often struggle to take their life-extending medication due to side effects and high costs. A new study found that interventions such as cost-cutting policies, mobile apps, and psychological counseling can increase medication adherence by nearly 1.5 times. Addressing mental health issues, particularly depression,...
Researchers developed a new formulation of doxorubicin that targets cancer cells while reducing cardiotoxicity. The protein-shell encapsulation increases specificity for cancer cells and decreases harm to healthy heart cells.
A new study finds that cost-cutting policy changes, mobile apps, and psychological strategies can increase medication adherence by nearly 1.5 times among breast cancer survivors. The study also highlights the importance of managing side effects through physical therapy, exercise, and behavioral counseling.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
Researchers found that certain anti-cancer compounds cause distinct nucleolar shapes and stress, which can be measured using a new classification system. This discovery could lead to improved understanding of why some drugs fail in clinical trials, providing a potential tool for identifying promising drug candidates.
A new targeted treatment called zolbetuximab has been shown to extend survival for patients with advanced gastric or gastroesophageal junction cancer that overexpresses a specific biomarker. The treatment significantly increased progression-free and overall survival, with improved results compared to standard chemotherapy.
Researchers developed SQUID, a computational approach to predict single-cell RNA composition from bulk analysis data. This allows for identification of chemoresistant cells and targeted therapy selection, improving treatment outcomes for patients.